Drugs / HS-10504
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07836504 | Sep 2026 → Sep 2027 expected | — | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07685041 | Jun → Nov 2026 expected | non-small cell lung carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07414953 | Mar 2026 → Apr 2027 expected | lung cancer | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06461156 | Jun 2024 → Dec 2026 expected | — | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-05-21 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Regulatory THE NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR FOURTH-GENERATION EGFR-TKI HS-10504 TABLETS FOR NSCLC hspharm.com ↗
The NMPA's Breakthrough Therapy Designation for HS-10504 tablets marks a significant step towards its availability to patients, as Hansoh Pharma continues to focus on unmet medical needs, and prioritize developing differentiated, high-quality innovative therapies to benefit more patients worldwide. |
| 2026-04-22 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results AACR 2026 | HANSOH PHARMA PRESENTED RESULTS OF HS-10504 (A NOVEL, POTENT, HIGHLY SELECTIVE, FOURTH-GENERATION EGFR TKI) FROM A FIRST IN HUMAN PHASE 1 STUDY IN PATIENTS WITH ADVANCED NSCLC hspharm.com ↗
In 34 efficacy-evaluable advanced NSCLC patients harboring EGFR C797S with or without T790M resistance mutations who received 400 mg once daily (QD), Objective Response Rate (ORR) was 52.9% and median Progression-Free Survival (PFS) was 9.6 months. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-21 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | THE NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR FOURTH-GENERATION EGFR-TKI HS-10504 TABLETS FOR NSCLC hspharm.com ↗ |
| 2026-04-22 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | AACR 2026 | HANSOH PHARMA PRESENTED RESULTS OF HS-10504 (A NOVEL, POTENT, HIGHLY SELECTIVE, FOURTH-GENERATION EGFR TKI) FROM A FIRST IN HUMAN PHASE 1 STUDY IN PATIENTS WITH ADVANCED NSCLC hspharm.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10504 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07836504 ↗ |
| Action | Inhibit | “tyrosine kinase inhibitor targeting EGFR C797S mutation” NCT06461156 ↗ |
| Route | Oral | “administered orally once daily” NCT06461156 ↗ |
| Target | EGFR | “targeting EGFR C797S mutation” NCT06461156 ↗ |